MMMarkus Magerl

Markus Magerl

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Markus Magerl has a total of 670 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regional Patterns in the Prevalence of Patient‐Reported Urticaria Aggravating Factors: A Multinational Mobile Health Study

    by Nuno Lourenço‐Silva, Ana Gimenez Arnau, Ivan Cherrez‐Ojeda, Jean Bousquet, Jonathan A. Bernstein, Luis Felipe Ensina, Silvia Mariel Ferrucci, Michihiro Hide, Andreas Kleinheinz, Emek Kocatürk, et al.

    Background: In chronic spontaneous urticaria (CSU), exacerbations are often associated with aggravating factors. However, the prevalence of patients having aggravating factors has been insufficiently studied. This mHealth study aimed to (i) estimate the prevalence of patient‐reported perceived aggravating factors for CSU across 10 countries, and (ii) identify factors associated with such triggers. Methods: We performed a cross‐sectional analysis of data from users of the CRUSE mobile application. The study included patients aged 15–74 years with self‐reported CSU. We assessed the frequency of reporting at least one of the following perceived aggravating factors: stress, food, exercise, low or high temperature, rubbing of the skin, infection, and medication. To correct for sample biases in age and sex distribution, we employed Multilevel Regression with Poststratification (MRP) models. In addition, we built logistic regression models to identify factors associated with perceived aggravating factor reporting. Results: Of the 12,243 included participants, 62.1% reported at least one perceived aggravating factor. Stress (31.1%) and rubbing of the skin (23.1%) were the most common. After MRP, the frequency of reporting at least one perceived aggravating factor ranged between 39.6% (Japan) and 83.7% (Brazil). The reporting frequency was lower in Asian than in Western countries. Female sex was independently associated with higher odds of reporting most perceived aggravating factors, except exercise and food. Younger age and lower disease control were associated with higher aggravating factor reporting. Conclusions: Patient‐reported perceived aggravating factors varied substantially across countries. Female sex, younger age, and poorer disease control were associated with increased reporting. Cross‐country differences may reflect biological, healthcare‐related, cultural, and psychosocial influences.

  • Open Access

    Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema

    by Markus Magerl, Kathrin Schön, Janine Ruhe, Felix Aulenbacher, Leonie Shirin Herzog, Thomas Buttgereit

    Background: Garadacimab, a first‐in‐class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long‐term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real‐life treatment outcomes at our Berlin Angioedema Center of Reference and Excellence (ACARE), the reasons for switching therapies, and approaches to tailoring treatment individually. Methods: In total, 29 patients (27 patients with HAE and 2 patients with angioedema due to acquired C1 inhibitor deficiency) were treated in regular care with garadacimab; 3 patients discontinued garadacimab due to lack of efficacy after loading dose or second dose and were excluded from analysis due to insufficient follow up. Ultimately, 26 patients were monitored for 26 weeks (median) using the angioedema control test (AECT) and the angioedema quality of life questionnaire (AE‐QoL). In seven patients, garadacimab from the open‐label‐VANGUARD study was continued in regular care. Patients who had previously participated in the study—provided they were symptom‐free—were offered the option, upon transitioning to routine care, to extend the interval between injections by alternating between three and four days. Patients who were switched to garadacimab in routine care were offered the same option if they were completely symptom‐free 2 months after starting the therapy. Results: Overall, 16 patients switched from previous LTP to garadacimab mostly at the end of their individual treatment interval and due to the prospect of higher efficacy and convenience. The injection interval could be extended in most patients (median, 42 days, range 31–56). The mean AECT and AE‐QoL improved clinically meaningfully, regardless of previous treatment (9.2–14.4 and 35.5–14.9 points, respectively), however, improvement in patients switched from previous LTP was less pronounced when compared to patients that switched from on‐demand treatment (11.2–14.5 vs. 6.7–14.2 points and 29.4–14.3 vs. 43.1–15.7 points, respectively). No side effects were reported. Conclusions: Garadacimab showed high efficacy and safety and the gradual extension of injection intervals presented underline its potential for longer dosing intervals that may further reduce treatment burden.

  • Open Access

    Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack‐Free Probability and Quality of Life Over 5 Years

    by Philip H. Li, F. Ida Hsu, Emel Aygören‐Pürsün, William R. Lumry, Jason Raasch, Ingo Pragst, Yinglei Li, Chiara Nenci, Marco Campioni, Markus Magerl

    Hereditary angioedema (HAE) attacks are recurrent, debilitating, and potentially life‐threatening. Across the clinical program, garadacimab long‐term prophylaxis demonstrated early onset and durable, sustained protection against HAE attacks and clinically meaningful improvements in health‐related quality of life (HRQoL). HAE treatment goals include total disease control (attack‐free) and normalization of life. Predicting treatment effect may aid shared decision‐making and choice of long‐term prophylaxis. Here, we report an attack‐free probability model predicting garadacimab treatment effect beyond available Phase 3 clinical data and explore the relationship between HRQoL and attack‐free duration. A generalized mixed‐effect Poisson model was developed and validated with data from the garadacimab pivotal Phase 3 (VANGUARD) and Phase 3 open‐label extension studies. Efficacy variables, including attack‐free probabilities, were predicted for simulated populations of garadacimab‐treated patients and assessed for goodness of fit. Analysis of covariance was used to assess the relationship between Angioedema Quality of Life questionnaire scores and attack‐free duration. Model‐predicted efficacy variables adequately reflected observed clinical data with high goodness of fit (Nakagawa–Schielzeth conditional R 2 : 74.3%). Following a 1‐month attack‐free period after garadacimab initiation, patients had a 60% cumulative probability of remaining attack‐free up to Month 25 and 49% up to 5 years. HRQoL improved with increasing duration of attack‐free periods, reaching minimal to no impairment after 6 months. This attack‐free probability model suggests long‐term effects of garadacimab over a 5‐year treatment period. Patients treated with garadacimab have the potential to live attack‐free for long periods of time, with substantial HRQoL improvements.

  • Open Access

    Update zur Diagnostik und Therapie von Angioödemen

    by Thomas Buttgereit, Markus Magerl

  • Open Access

    Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study

    by Andrea Zanichelli, Walter A. Wuillemin, Markus Magerl, Andreas Recke, Mauro Cancian, Emel Aygören‐Pürsün, Ramón Lleonart Bellfill, Aharon Kessel, Tamar Kinaciyan, Robin Lochbaum, et al.

    Background: Lanadelumab has been approved for hereditary angioedema (HAE) long‐term prophylaxis since 2018. The Phase 4, prospective ENABLE Study (NCT04130191) evaluated the long‐term effectiveness and safety of lanadelumab in clinical practice across Europe and the Middle East. Methods: Patients with HAE aged ≥ 12 years initiating lanadelumab treatment (300 mg every 2 weeks) per approved product labeling were recruited from Austria, Germany, Israel, Italy, Kuwait, Spain, and Switzerland and followed for up to 36 months (± 30 days). The primary objective was to evaluate lanadelumab effectiveness for HAE attack prevention. Safety and patient‐reported health‐related quality of life (HRQoL) were also evaluated. Results: Outcomes were analyzed in 138 patients (mean [range] age: 41.0 [14–79] years; 62.3% female; 92.0% HAE‐C1INH‐Type1), of whom > 60% extended dosing intervals by Month 12. Over a mean ± SD treatment duration of 28.6 ± 9.8 months, mean ± SD patient‐reported HAE attack rate decreased from 3.88 ± 3.43 attacks/month pre‐lanadelumab to 0.30 ± 0.53 attacks/month (mean decrease, 84% [median 96%]). The incidence‐rate ratio was 0.07 (95% CI: 0.06–0.10), reflecting a 93% reduction from modeled pre‐lanadelumab rates. Overall, 95/138 patients reported treatment‐emergent adverse events (TEAEs); most were unrelated to lanadelumab (82.3%). Of the 17.7% of TEAEs considered treatment‐related, injection‐site reactions, headache, fatigue, and asthenia occurred in > 1 patient. Before lanadelumab initiation, most patients reported moderate‐to‐large HRQoL impairments; clinically meaningful improvements were observed 1 month after lanadelumab initiation and sustained throughout the study. Conclusions: Real‐world data from ENABLE demonstrated long‐term effectiveness of lanadelumab in patients with HAE aged ≥ 12 years and a safety profile consistent with previous clinical studies.

  • Open Access

    Optimizing conversations on treatment management in hereditary angioedema: healthcare professional and patient perspectives on long-term prophylaxis and shared decision-making

    by Markus Magerl, Emel Aygören-Pürsün, Jens Greve, Andreas Recke, Petra Staubach-Renz, Inmaculada Martinez-Saguer, Lucia Schauf, Diane Langenbacher, Danielle Christmas, Tamara Ray, et al.

    Introduction: Hereditary angioedema (HAE), characterized by unpredictable attacks of subcutaneous or submucosal edema, can significantly impact patient quality of life (QoL). Despite advances in long-term prophylaxis (LTP), achieving complete control of HAE is challenging, making shared decision-making (SDM) critical for tailored HAE management. This investigation explores the dynamics of healthcare professional (HCP)–patient conversations concerning HAE management, and identifies barriers to SDM, LTP initiation and strategies that may overcome these to optimize patient QoL. Methods: The investigation was conducted in Germany. HCPs managing patients with HAE participated in 60 min interviews and led simulated patient consultations. 30 min interviews with patients with HAE were also conducted. Results: Ten HCPs and eight patients with HAE were interviewed. In the simulated consultations, most HCPs recommended LTP based on high attack frequency and substantial impact on QoL. Interviews revealed that HCPs typically initiate discussions on LTP by assessing disease burden, focusing on attack frequency and QoL. These treatment discussions also highlighted the need for improved communication with patients about the LTP treatments that are available to them. However, many HCPs lacked awareness of updated treatment guidelines and faced challenges in reassuring patients about the long-term safety and efficacy of newer LTP options. All patients who were initiated on LTP experienced positive results, including improved QoL and reduced fear of attacks. Those who declined LTP cited low attack frequency on their acute treatment and concerns about burden of treatment and long-term effects. Key barriers to effective SDM included time constraints during routine consultations, absence of clear SDM guidance, and a lack of jargon-free information to foster proactive patient engagement. Conclusion: This research highlights opportunities to enhance HCP–patient conversations concerning the management of HAE. Inconsistencies between positive patient experiences with LTP and real-world prescription rates emphasize the need for improved SDM practices. Enhancing HCP awareness of patient perspectives, managing time constraints in consultations, and providing unbiased, patient-friendly information may help bridge these gaps and improve communication and ultimately patient QoL. The findings underscore the importance of further research to develop guidelines that prioritize SDM and patient empowerment in HAE management.

  • Open Access

    Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis

    by Timothy J. Craig, Mar Guilarte, Huamin Henry Li, John Anderson, Inmaculada Martinez Saguer, Joshua S. Jacobs, Raffi Tachdjian, Henriette Farkas, William H. Yang, Isao Ohsawa, et al.

    Garadacimab (monoclonal antibody inhibiting activated factor XII [FXIIa]) is approved for long-term prophylaxis (LTP) against hereditary angioedema (HAE) attacks. Due to the novelty of FXIIa inhibition and the lifelong need for HAE LTP, long-term evaluation of garadacimab is important. Pooling data from multiple studies can provide valuable insights into treatment effects over longer durations. We report the integrated summary of safety (ISS) and efficacy (ISE) of garadacimab LTP across the HAE clinical development program. The ISS comprised data from phase 2 (13-week placebo-controlled period, 75/200/600 mg monthly or 400 mg every 2 weeks; ≥ 44-week open-label period, 200/600 mg monthly; NCT03712228), pivotal phase 3 (6 months; 200 mg monthly; NCT04656418), and ≥ 12-month phase 3 open-label extension (OLE) studies (200 mg monthly; NCT04739059). The ISE comprised data from phase 3 studies. Endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) per protocol, and efficacy. At data cutoff (June 15, 2024), median garadacimab exposure (ISS: any dose, n = 172) was 2.5 (range 0.2-5.5) years. Overall rates of TEAEs and garadacimab-related TEAEs were 2.8/patient-year and 0.2/patient-year, respectively. No deaths occurred; four TEAEs led to treatment discontinuation. Eleven patients experienced SAEs (0 garadacimab-related). No garadacimab-related AESIs were reported; one unrelated AESI was observed with garadacimab 600 mg (epistaxis; mild; resolved). The most common garadacimab-related TEAEs were mild/moderate injection-site reactions. In the ISE (median exposure 2.5 [range 0.3-3.2] years), the mean (95% confidence interval) monthly attack rate was 0.2 (0.1, 0.2) with garadacimab (n = 164), corresponding to a 94.9% (93.1, 96.7) reduction from run-in (3.5 [3.2, 3.9]). These integrated data, representing the longest garadacimab exposure reported to date, confirm the favorable long-term safety profile of garadacimab (exposure ≤ 5.5 years), and durable efficacy with sustained protection against HAE attacks (exposure ≤ 3.2 years). ClinicalTrials.gov identifiers, NCT03712228, NCT04656418, NCT04739059.

  • Global Real-World Validation of First-Day Urticaria Activity Score (UAS1)

    by Lanka Huidong Su, Bernardo Sousa Pinto, Aiste Ramanauskaite, Ellen Witte-Händel, Ana Gimenez Arnau, Ivan Cherrez-Ojeda, Emek Kocatürk, Karsten Weller, Jean Bousquet, Markus Magerl, et al.


  • Top Cited Papers
    Open Access

    The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

    by Torsten Zuberbier, Zainab AbdulHameed Ansari, Amir H. Abdul Latiff, M. M. Abuzakouk, Maria Socorro Agcaoili‐De Jesus, Rosana C. Agondi, Mona Al‐Ahmad, Abdullah A. Alangari, H. Alhameli, Cesar D. Alonso Bello, et al.

    This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.


  • Open Access

    Algorithms in Allergy: Hereditary Angioedema

    by Konrad Bork, Markus Magerl, Emel Aygören‐Pürsün, Henriette Farkas